Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic

August 9, 2026

BioInsights USA

Overview

July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals’ CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and transfusion-dependent beta-thalassemia. Concurrently, Umoja Biopharma secured FDA IND approval for its in vivo CAR-T cell therapy, UB-VV400, paving the way for the first international patient treatments for solid tumors with this innovative modality. This period also saw robust governmental support, including ARPA-H’s commitment of up to $160 million for scalable in vivo gene editing for rare diseases, highlighting accelerating regulatory momentum for next-generation therapies.

In Depth

Key Findings

July 2026 was a landmark month for gene and cell therapy, characterized by a significant expansion in therapeutic access, particularly for pediatric patients, and the acceleration of in vivo CAR-T cell therapy into solid tumor indications. Vertex Pharmaceuticals’ gene therapy CASGEVY received expanded U.S. FDA approval for patients aged 2 and older with sickle cell disease and transfusion-dependent beta-thalassemia, marking a pivotal advancement for this young population with limited treatment options. Simultaneously, Umoja Biopharma’s investigational new drug (IND) application for its in vivo CAR-T cell therapy, UB-VV400, gained FDA approval, setting the stage for the first international patient treatments using an in vivo CAR-T approach for solid tumors.

Technical / Clinical Details

CASGEVY employs CRISPR/Cas9 gene-editing technology in an ex vivo setting, modifying a patient’s own hematopoietic stem cells outside the body before reinfusion to correct the underlying cause of red blood cell disorders. The expanded approval for pediatric patients aged two and above is based on clinical trial data demonstrating sustained efficacy and a favorable safety profile in this younger cohort. In parallel, Umoja Biopharma’s UB-VV400 utilizes an in vivo strategy, designed to induce CAR-expressing T cells directly within the patient. This eliminates the need for complex ex vivo manufacturing, potentially streamlining the treatment process and dramatically improving accessibility for solid tumor patients. This groundbreaking approach is also slated for trials targeting recurrent/refractory B-cell malignancies, showcasing its broad potential across various cancer types.

Background & Context

Gene and cell therapies are rapidly transforming the treatment landscape for previously intractable diseases. The FDA has been actively facilitating the development of these innovative therapies through expedited programs such as Regenerative Medicine Advanced Therapy (RMAT) designations. In vivo CAR-T cell therapy holds immense promise for overcoming the manufacturing and logistical challenges inherent in conventional CAR-T therapies, potentially reducing treatment costs and turnaround times, garnering substantial industry-wide anticipation. Furthermore, the Advanced Research Projects Agency for Health (ARPA-H) announced an investment of up to $160 million into scalable in vivo gene editing technologies for rare diseases, signaling strong government support for innovation in this sector. This governmental backing further fuels the regulatory momentum for allogeneic transplantation and solid tumor cell therapies.

Strategic Significance & Outlook

The expanded pediatric indication for Vertex’s CASGEVY signifies gene therapy reaching a broader patient demographic, with the potential for improved long-term outcomes through earlier intervention. The clinical initiation of Umoja’s in vivo CAR-T therapy, UB-VV400, represents a new frontier in solid tumor treatment, and its success could profoundly reshape oncology care. ARPA-H’s funding will accelerate the development of in vivo gene editing technologies for rare diseases, contributing to future therapeutic diversification. These advancements collectively underscore a powerful trajectory for the growth of the iPS cell and regenerative medicine fields, driving towards more effective and accessible treatment options for a wider patient population globally.

Source: https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/3912/industry-insights-expanding-access-across-the-field-from-pediatric-approvals-to-the-first-solid-tumor-cart

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.